Covid-19 : quelle prise en charge pour l’automne 2022 ? [COVID-19, how to treat the disease during Fall 2022?]
Fiche du document
2 novembre 2022
- doi: 10.53738/REVMED.2022.18.802.2077
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.802.2077
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36326227
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C2059E681DC49
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-05-02 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
illnessCiter ce document
V. Chollet et al., « Covid-19 : quelle prise en charge pour l’automne 2022 ? [COVID-19, how to treat the disease during Fall 2022?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.802.2077
Métriques
Partage / Export
Résumé
Since the arrival of COVID-19, we have witnessed a series of new variants and new therapies, and it is therefore becoming difficult to stay up to date on the best management of an outpatient infected with SARS-CoV-2. In a patient at risk of an unfavorable evolution in the first 5 days of illness, the antiviral Paxlovid is recommended. Evusheld, administered in the hospitals, is recommended in patients with a documented negative serology, for treatment in early disease or as a pre-exposure prophylaxis. The activity of monoclonal antibodies seems to be reduced with the new variants. Dexamethasone is reserved for the hospital management of an oxygen-dependent patient. There is no place for antibiotic therapy apart from additional bacterial infection.